Can Lactobacillus reuteri DSM 17938 be used in term infants ≤3 months old with infantile colic?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 17, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Yes, Lactobacillus reuteri DSM 17938 can be used in small infants for colic, but its efficacy is strongly dependent on feeding type—it is highly effective in breastfed infants but shows minimal to no benefit in formula-fed infants.

Evidence-Based Recommendation

For breastfed infants ≤3 months with infantile colic, use L. reuteri DSM 17938 as first-line probiotic therapy 1. The ESPGHAN working group specifically recommends this strain for treatment of infantile colic, especially in breastfed babies 1.

Efficacy by Feeding Type

Breastfed Infants (Strong Evidence)

  • Treatment success is twice as likely compared to placebo at 21 days 2
  • Reduces crying/fussing time by approximately 25 minutes per day at day 21 2
  • Number needed to treat: 2.6 (meaning only 3 breastfed infants need treatment for one to benefit) 2
  • Recent 2026 meta-analysis confirms 43% reduction in infant distress time at day 7, increasing to 62% by day 21 3
  • Meta-analysis shows 6.98 times higher odds of treatment response (≥50% reduction in crying) 4

Formula-Fed Infants (Insufficient Evidence)

  • Effects are insignificant in formula-fed infants 2
  • One large Australian community trial showed formula-fed infants actually cried/fussed 49 minutes MORE in the probiotic group 5
  • Current evidence does not support routine use in formula-fed populations 2, 5

Dosing and Administration

  • Dose: 1 × 10⁸ CFU daily (100 million colony-forming units) 4, 2
  • Duration: 21 days minimum for full effect 3, 4
  • Timing: Effects begin within 7 days but peak at 21 days 3

Safety Profile

L. reuteri DSM 17938 has an excellent safety record in term infants 1, 6:

  • GRAS (Generally Recognized As Safe) status 6
  • No study-related adverse events in clinical trials 5
  • No increased risk of sepsis 4

Important Safety Caveats

The European Paediatric Association recommends caution in 1:

  • Premature neonates
  • Immunocompromised patients
  • Critically ill patients
  • Those with central venous catheters
  • Cardiac valvular disease
  • Short-gut syndrome

Clinical Algorithm

Step 1: Confirm diagnosis

  • Crying/fussing >3 hours/day, >3 days/week in otherwise healthy infant <3 months
  • Rule out red flags (fever, poor weight gain, vomiting, bloody stools)

Step 2: Determine feeding type

  • If breastfed → Prescribe L. reuteri DSM 17938 (1 × 10⁸ CFU daily for 21 days)
  • If formula-fed → Consider alternative approaches (see below)

Step 3: Monitor response

  • Assess at 7 days (expect 40% reduction in distress time)
  • Reassess at 21 days (expect 60% reduction in distress time)
  • If no response by 21 days in breastfed infant, reconsider diagnosis

Alternative for Formula-Fed Infants

For formula-fed infants, recent evidence suggests considering Bifidobacterium breve BR03 + B. breve B632 combination instead, which shows preventive and symptomatic benefit in this population 7. However, this evidence is less robust than for L. reuteri in breastfed infants.

Key Pitfalls to Avoid

  1. Don't use in formula-fed infants expecting same results as breastfed - the evidence simply doesn't support it 2, 5
  2. Don't stop treatment before 21 days - full effect requires 3 weeks 3
  3. Don't use in premature infants without specialist consultation - safety data primarily exists for term infants 1
  4. Ensure pharmaceutical-grade product - contamination risks exist with non-regulated products 6

Mechanism of Action

The probiotic works through 6:

  • Production of reuterin (antimicrobial metabolite)
  • Modulation of GI motility via microvesicles
  • Reduction of low-grade gut inflammation
  • Restoration of microbial diversity (reduces gas-producing coliforms)

The lack of efficacy in formula-fed infants likely reflects absence of synergistic factors present in human breast milk 2.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.